Welcome to our dedicated page for Noveris Health Sciences news (Ticker: MYCOF), a resource for investors and traders seeking the latest updates and insights on Noveris Health Sciences stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Noveris Health Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Noveris Health Sciences's position in the market.
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) has achieved a significant milestone by successfully completing the world’s first international legal export of dried psilocybin mushrooms. The company harvested 20 kilograms of mushrooms in December 2020, now forming a solidified commercial supply chain for psilocybin. This accomplishment allows Mydecine to support its research and supply other licensed facilities globally. The CEO stated that their natural-sourced psilocybin will be a cost-effective alternative to synthetic versions, which could enhance the company's R&D and market position.
Mydecine Innovations Group (CSE: MYCO, OTC: MYCOF) has successfully closed a bought-deal public offering, issuing 34.5 million units at C$0.50 each, raising C$17.25 million. This offering, led by Canaccord Genuity, includes an over-allotment option exercised in full. The company plans to utilize the proceeds for clinical trials, expanding its intellectual property portfolio, drug pipeline development, and general working capital. Each unit comprises one common share and a warrant, which will allow for further investment opportunities.
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) has filed its final short form prospectus in relation to its previously announced bought deal offering. The company plans to raise C$15 million by offering 30,000,000 units at C$0.50 each, with warrants exercisable at $0.70 over 36 months. An over-allotment option for an additional 4,500,000 units is also available. Proceeds will fund clinical trials, expand intellectual property, and support the development of its drug pipeline. The offering is expected to close by February 12, 2021, pending necessary approvals.
Mydecine Innovations Group (CSE:MYCO | OTC:MYCOF) has filed amended financial statements for the nine months ended September 30, 2020, reflecting significant adjustments. The revised reports show a decrease in total assets by $493,214, an increase in total liabilities by $1,830,594, and a drop in shareholders' equity by $2,323,808. Additionally, the net loss increased by $2,282,519 during this period. Key changes involve adjustments related to acquisitions and the write-off of inventory from subsidiaries, which amount to $458,921. All figures are in Canadian dollars.
Mydecine Innovations Group announces the appointment of Josephine Wu to its Board of Directors, aiming to enhance growth and strategic direction. Wu, with over 18 years in hedge fund and healthcare investment, replaces Michael Connolly, who resigned. This leadership change contributes positively to governance as the Caveat Emptor designation on OTC markets is lifted, facilitating Mydecine's compliance with U.S. trading regulations. The company focuses on developing innovative solutions in mental health, leveraging Wu's extensive experience to further its business model and partnerships.
Mydecine Innovations Group (CSE: MYCO) has received Conditional Approval to migrate and uplist its common shares to the NEO Exchange, enhancing its accessibility to retail and institutional investors. The final approval hinges on meeting NEO's listing requirements. This uplisting aims to increase liquidity and visibility for Mydecine, as noted by CEO Josh Bartch. The current trading symbol 'MYCO' will remain unchanged, not affecting existing shareholders' trading capabilities.
Mydecine Innovations Group (CSE: MYCO, OTC: MYCOF) has announced a bought deal offering, filing a preliminary prospectus to raise C$15 million through the sale of 30 million units at C$0.50 each. Each unit consists of one common share and a warrant, exercisable for three years at $0.70. The offering includes an over-allotment option for an additional 4.5 million units. Funds will support clinical trials, expand the drug pipeline, and for general working capital. The offering is expected to close around February 3, 2021, pending necessary approvals.
Mydecine Innovations Group (CSE: MYCO) has appointed SHIM & Associates LLP as its new auditor, replacing MNP LLP. The change was necessitated as MNP lacked the capacity to review the Company’s interim financial statements for its bought deal offering due to a busy period. A Notice of Change of Auditor has been filed on SEDAR. The Canadian Securities Exchange has neither approved nor disapproved the contents of the news release.
Mydecine Innovations Group has requested the retraction of a press release titled “Mydecine Innovations Group Upsizes Previously Announced Bought Deal,” issued by Miller Thomson LLP.
This request is made due to the lack of prior authorization from Mydecine, indicating potential issues in communications and press management.
Miller Thomson LLP has requested the cancellation of their press release regarding a C$10 million bought deal offering by Mydecine Innovations Group. The request indicates that the press release was disseminated without the company's authorization, raising concerns about proper communication protocols.